1. Home
  2. HALO vs BIO Comparison

HALO vs BIO Comparison

Compare HALO & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HALO
  • BIO
  • Stock Information
  • Founded
  • HALO 1998
  • BIO 1952
  • Country
  • HALO United States
  • BIO United States
  • Employees
  • HALO N/A
  • BIO N/A
  • Industry
  • HALO Biotechnology: Biological Products (No Diagnostic Substances)
  • BIO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • HALO Health Care
  • BIO Industrials
  • Exchange
  • HALO Nasdaq
  • BIO Nasdaq
  • Market Cap
  • HALO 7.6B
  • BIO 7.7B
  • IPO Year
  • HALO N/A
  • BIO N/A
  • Fundamental
  • Price
  • HALO $76.90
  • BIO $280.09
  • Analyst Decision
  • HALO Buy
  • BIO Strong Buy
  • Analyst Count
  • HALO 8
  • BIO 4
  • Target Price
  • HALO $70.25
  • BIO $333.50
  • AVG Volume (30 Days)
  • HALO 2.0M
  • BIO 220.7K
  • Earning Date
  • HALO 10-30-2025
  • BIO 10-29-2025
  • Dividend Yield
  • HALO N/A
  • BIO N/A
  • EPS Growth
  • HALO 68.93
  • BIO N/A
  • EPS
  • HALO 4.37
  • BIO 11.49
  • Revenue
  • HALO $1,178,672,000.00
  • BIO $2,554,200,000.00
  • Revenue This Year
  • HALO $32.57
  • BIO $2.12
  • Revenue Next Year
  • HALO $23.25
  • BIO $2.90
  • P/E Ratio
  • HALO $17.65
  • BIO $24.46
  • Revenue Growth
  • HALO 34.97
  • BIO N/A
  • 52 Week Low
  • HALO $42.01
  • BIO $211.43
  • 52 Week High
  • HALO $77.60
  • BIO $387.99
  • Technical
  • Relative Strength Index (RSI)
  • HALO 77.94
  • BIO 48.12
  • Support Level
  • HALO $74.52
  • BIO $276.52
  • Resistance Level
  • HALO $76.28
  • BIO $298.00
  • Average True Range (ATR)
  • HALO 1.63
  • BIO 7.65
  • MACD
  • HALO -0.06
  • BIO -2.84
  • Stochastic Oscillator
  • HALO 88.60
  • BIO 14.28

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: